UsAgainstAlzheimer's 2020 Annual Report

The UsAgainstAlzheimer's 2020 Annual Report features milestones from this past year as well as highlights from a decade of impact in the fight against Alzheimer's disease.

New Data Spotlights the Congressional Districts with the Highest Prevalence of Alzheimer’s among Blacks and Latinos

UsAgainstAlzheimer’s Center for Brain Health Equity released a new data brief highlighting the 41 congressional districts with the highest prevalence of Alzheimer’s disease and related dementias (ADRD) among Black Americans and Latinos in the traditional Medicare program. The brief details how government leaders can take action to help these hard-hit communities of color.

New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

UsAgainstAlzheimer’s calls on Biogen, the FDA and insurers to come together to solve four key issues that are critical for patients: affordability, equity, the length and diversity of the Phase 4 confirmatory trial, and who is most likely to benefit from the drug.

UsAgainstAlzheimer’s 2021 Virtual Advocacy Summit: Unlocking the Promise of Brain Health

UsAgainstAlzheimer's will bring together policy experts, advocates, and health system leaders to discuss and act on policy solutions that can help make the promise of brain health a reality for all communities. From early detection to health equity and economic justice, UsAgainstAlzheimer's brain health agenda puts patients, families, and communities first.

UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

UsAgainstAlzheimer’s issued the following statement from George Vradenburg, chairman and co-founder, on the Food and Drug Administration’s decision to approve Biogen’s aducanumab, the first disease-modifying therapy for early-stage Alzheimer’s.

Say Hello to BrainGuide

Our new platform BrainGuide™ was featured on The TODAY Show. It empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.

UsAgainstAlzheimer's 2020 Annual Report

New Data Spotlights the Congressional Districts with the Highest Prevalence of Alzheimer’s among Blacks and Latinos

New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

UsAgainstAlzheimer’s 2021 Virtual Advocacy Summit: Unlocking the Promise of Brain Health

UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

Say Hello to BrainGuide

UsAgainstAlzheimer's: Working to End Alzheimer's Disease  

The Alzheimer’s pandemic is the health and social economic crisis of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.

We bring all of “Us” together to:

In the past decade, progress has been made, with more hope on the horizon now than ever before.

But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.

Recent News and Blog Posts

  • July 29, 2021

    UsAgainstAlzheimer’s Praises Progress in Alzheimer’s Funding in House Appropriations Bill

    UsAgainstAlzheimer’s (UsA2) praised the progress made in the Alzheimer’s disease and related spending provisions...

    Read more
  • George Vradenburg

    UsA2’s 2020 Annual Report Chronicles a Decade of Impact

    In the 10 years since we founded UsAgainstAlzheimer’s, we have seen enormous progress in the...

    Read more
  • July 20, 2021

    UsAgainstAlzheimer’s Center for Brain Health Equity Spotlights the 41 Congressional Districts with the Highest Prevalence of Alzheimer’s among Blacks and Latinos

    UsAgainstAlzheimer’s Center for Brain Health Equity released a new data brief today...

    Read more
  • July 19, 2021

    UsAgainstAlzheimer’s Praises Proposed New National Risk Reduction Goal for Alzheimer’s and Related Dementias

    UsAgainstAlzheimer’s today praised the decision by the National Alzheimer’s Project Act (NAPA)...

    Read more
  • June 24, 2021

    UsAgainstAlzheimer’s Applauds Progress with New Lilly and Eisai/Biogen Drug Treatments That Offer the Promise of More Choices to Alzheimer’s Patients

    UsAgainstAlzheimer’s today issued the following statement from George Vradenburg, chairman and co-founder...

    Read more
  • June 21, 2021

    New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

    The FDA’s approval of Aduhelm is a breakthrough in the fight to...

    Read more

Reports

  • Resources

    2020 Annual Report

    In these pages, you will find highlights of the game-changing accomplishments and tremendous progress of UsAgainstAlzheimer's and our partners in the year of 2020. 

  • Resources

    A-LIST Pulse of the Community: Volume 8, June 2021

    The UsAgainstAlzheimer’s A-LIST® is an online community of more than 8,600 people living with Alzheimer’s and other dementias, current and former caregivers, and those concerned about brain health, who have...

  • Resources
    Thumbnail

    Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

    The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer’s. This report found that...